期刊文献+

外涂普萘洛尔凝胶对浅表型增殖期婴幼儿血管瘤患者血浆VEGF、bFGF和MMP-9的影响 被引量:17

Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type
原文传递
导出
摘要 目的 探讨普萘洛尔凝胶对浅表型增殖期婴幼儿血管瘤患儿(IHs)血浆血管内皮生长因子(VEGF)、碱性成纤维生长因子(bFGF)和基质金属蛋白酶-9(MMP-9)的影响.方法 选取2013年2月至2014年2月厦门大学附属东方医院普通外科,采用普萘洛尔凝胶治疗的33例浅表型增殖期婴幼儿血管瘤患儿的临床资料,采用Achauer分级标准评估疗效,ELISA检测治疗前和治疗后l、3个月时血浆VEGF、bFGF和MMP-9含量,并与30例健康婴幼儿进行对照.健康婴幼儿和治疗前婴幼儿血管瘤患儿2组间计量资料,采用Mann-Whitney U-test检验,婴幼儿血管瘤患儿治疗前及治疗后1、3个月,此3个时间点中任意2个时间点的比较,采用配对Wilcoxon符合秩检验,数据采用SPSS 13.0进行分析.结果 IHs治疗l、3个月后的有效率分别为45.45%和81.82%.患儿治疗前血浆VEGF和MMP-9含量分别为(362.16 ±27.29) pg/ml和(1 376.41±42.15) pg/ml,均高于健康婴幼儿的(85.63 ±8.14) pg/ml和(687.27 ±44.15) pg/ml,P<0.05;bFGF在IHs和健康婴幼儿间无明显差异[(235.94±35.43) pg/ml和(176.03±13.60) pg/ml],P>0.05.IHs治疗后1个月,VEGF和bFGF含量分别为(271.51 ±18.59) pg/ml和(135.85 ±12.66) pg/ml,较治疗前显著减少,P <0.05;治疗后3个月VEGF和bFGF含量分别为(240.80±19.89) pg/ml和(107.31±5.82)pg/ml,与治疗前比较,P<0.05.治疗后l、3个月,MMP-9含量分别为(1 321.18±48.74) pg/ml和(1 468.68 ± 32.78) pg/ml,未见明显下降,P>0.05.结论 普萘洛尔凝胶治疗浅表型增殖期婴幼儿血管瘤致血浆VEGF、bFGF含量减少,可能与其抑制婴幼儿血管瘤的增殖有关. Objective To investigate the effect of topical propranolol gel on the levels of plasma vascular endothelial growth factor (VEGF),basic fibroblastic growth factor (bFGF) and matrix metalloproteinases-9 (MMP-9) in proliferating infantile hemangiomas (IHs) of superficial type.Methods 33 consecutive children with superficial IHs were observed pre-treatment,1 and 3 months after application of topical propranolol gel for the levels of plasma VEGF,MMP-9 and bFGF by enzyme-linked immunosorbent assay (ELISA) in Department of General Surgery of Dongfang Hospital from February 2013 to February 2014.The plasma results of IHs were compared with those of 30 healthy infants.The clinical efficacy in IHs was evaluated by Achauer system.Differences of plasma results between the healthy group and the IHs group pre-treatment were analyzed using Mann-Whitney U-test.Paired sample comparisons of any two time points of pre-treatment,1 month and 3 months after treatment in IHs were evaluated by Wilcoxon signed-rank test.Results The clinical efficiency of topical propranolol gel at 1,3 months after application were 45.45%,81.82% respectively.The levels of plasma VEGF and MMP-9 in patients pretreatment were higher than those in healthy infants [(362.16 ±27.29) pg/ml vs (85.63 ± 8.14) pg/ml,(1 376.41 ±42.15) pg/ml vs (687.27 ±44.1) pg/ml,P〈0.05],but the level ofbFGF did not show significant difference [(176.03 ± 13.60) pg/ml vs (235.94 ± 35.43) pg/ml,P 〉 0.05].The concentrations of VEGF and bFGF at 1,3 months after treatment decreased obviously [(271.51 ± 18.59) pg/ml vs (362.16 ±27.29) pg/ml,(135.85 ±12.66) pg/ml vs (176.03 ±13.60) pg/ml],1 month after treatment vs pre-treatment,P 〈 0.05; (240.80 ± 19.89) pg/ml vs (362.16 ± 27.29) pg/ml,(107.31 ±5.82) pg/ml vs (176.03 ± 13.60) pg/ml,3 month after treatment vs pre-treatment,P 〈 0.05,whereas the levels of plasma MMP-9 declined slightly [(1 321.18 ±48.74) pg/ml vs (1 376.41 ± 42.15) pg/ml,(1 468.68 ±32.78) pg/ml vs (1 376.41 ±42.15) pg/ml,P〉0.05].Conclusions Propranolol gel may suppress the proliferation of superficial infantile hemangiomas by reducing VEGF and hFGF.
出处 《中华整形外科杂志》 CAS CSCD 北大核心 2015年第4期268-273,共6页 Chinese Journal of Plastic Surgery
基金 福建省科技厅社会发展重点项目(2011Y0042)
关键词 婴幼儿血管瘤 普萘洛尔 投药 局部 血浆 血管内皮生长因子 碱性成纤维生长因子 基质金属蛋白酶-9 Infantile hemangiomas Propranolol Administration, topical Plasma Vascular endothelial growth factor Basic fibroblastic growth factor Matrix metalloproteinases-9
  • 相关文献

参考文献5

二级参考文献45

  • 1李劲松,陈伟良,李海刚,王建广,程慧琳,何璇凌.婴幼儿血管瘤和血管畸形组织中一氧化氮合酶的表达及意义[J].中国口腔颌面外科杂志,2004,2(3):169-172. 被引量:2
  • 2Qi Fang Li Xiang Rui Wang Yue Wu Yang Han Lin.Hypoxia upregulates hypoxia inducible factor(HIF)-3α expression in lung epithelial cells: characterization and comparison with HIF-1α[J].Cell Research,2006,16(6):548-558. 被引量:16
  • 3常青,秦仁义,黄涛,高军,冯延平.反义缺氧诱导因子-1α对胰腺癌生长转移的影响[J].中华实验外科杂志,2006,23(7):837-839. 被引量:21
  • 4[1]Phung TL,Hochman M,Mihm MC,et al.Current knowledge of the pathogenesis of infantile hemangiomas[J].Arch Facial Plast Surg,2005,7(5):319-321.
  • 5[2]Smolinski KN,Yan AC.Hemangiomas of infancy:clinical and biological characteristics[J].Clin Pediatr,2005,44(9):747-766.
  • 6[3]Marler JJ,Fishman SJ,Kilrog SM,et al.Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies[J].Pediatrics,2005,116(1):38-45.
  • 7[4]Kim ST,Park SH,Kim SK,et al.Potential role of Homer-2a on cutaneous vascular anomaly[J].J Korean Med Sci,2002,17(5):636-640.
  • 8[5]Ritter MR,Moreno SK,Dorrell MI,et al.Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis:a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution[J].Lymphat Res Biol,2003,1(4):291-299.
  • 9[6]Martinez MI,Scanchez-Carpintero I,North PE,et al.Infantile hemangioma:clinical resolution with 5% imiquimod cream[J].Arch Dermatol,2002,138(7):881-884.
  • 10[7]Nguyen VA,Furuapter C,Romani N,et al.Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology[J].Hum Pathol,2004,35(6):739-744.

共引文献54

同被引文献117

引证文献17

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部